Join
Live feed
·
INSIDERFilingvia Quantisnow
Regeneron Pharmaceuticals Inc. logo

EVP Research and Development Stahl Neil covered exercise/tax liability with 466 shares, decreasing direct ownership by 0.94% to 49,133 units (SEC Form 4)

ByQuantisnow·Wall Street's wire, on your screen.
REGN· Regeneron Pharmaceuticals Inc.
Health Care
Original source

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track REGN (Regeneron Pharmaceuticals Inc.) and more on Quantisnow.